Background: Doravirine is a novel, potent, HIV-1 non-nucleoside reverse transcriptase inhibitor that is primarily metabolized by oxidation via CYP3A4. Based on in vitro data, doravirine is a substrate of P-gp but not of OATP1B1. This study assessed the impact of single dose (SD) and multiple dose (MD) rifampin administration on the pharmacokinetics (PK) of doravirine. After multiple dosing, rifampin is a strong inducer of CYP3A4, while SD administration of rifampin was performed to assess the effects of hepatic OATP1B1 inhibition and intestinal P-gp inhibition on the absorption and metabolism of doravirine.
Methods: This was an open-label, 2-period, fixed-sequence study in healthy adult men (n=11). In Period 1, a SD of 100 mg doravirine was administered on Day 1. In Period 2, following a 7-day washout, a SD of 600 mg rifampin and 100 mg doravirine were coadministered on Day 1. Following a 3-day washout, 600 mg rifampin was administered once daily for 15 days (Days 4-18) and 100 mg doravirine was coadministered on Day 17. Safety evaluations were performed throughout the study.
Results: There were no serious clinical or laboratory adverse experiences (AEs) and all reported AEs were judged as mild in intensity. Following coadministration of single doses of rifampin and doravirine, the geometric mean ratio (GMR) (90% confidence interval [CI]) (doravirine + SD rifampin/doravirine) for AUC0-∞ and C24 were 0.91 (0.78, 1.06) and 0.90 (0.80, 1.01), respectively, suggesting that OATP1B1 inhibition does not impact the PK of doravirine. The GMR (90% CI) for Cmax were 1.40 (1.21, 1.63), indicating that P-gp inhibition may increase doravirine Cmax. After coadministration with multiple doses of rifampin, doravirine concentrations were significantly reduced as expected based on the role of CYP3A4 in doravirine metabolism. The GMRs (doravirine + MD rifampin/doravirine) and 90% CIs for AUC0-∞, C24, and Cmax were 0.12 (0.10, 0.15), 0.03 (0.02, 0.04), and 0.43 (0.35, 0.52), respectively.
Conclusions: Doravirine was generally well tolerated when administered alone or with rifampin. Inhibition of OATP1B1 and P-gp by SD rifampin did not have a clinically meaningful effect on the PK of doravirine. Multiple dosing of rifampin significantly reduced doravirine AUC0-∞, Cmax and C24. Thus, doravirine should not be administered with strong CYP3A4 inducers.